Patient-specific 3D-printed templates enabled efficient brachytherapy for complex cervical cancer
Template-guided implantation achieved a median HR-CTV D90 of 92.9 Gy with low severe toxicity across 555 brachytherapy fractions.
Template-guided implantation achieved a median HR-CTV D90 of 92.9 Gy with low severe toxicity across 555 brachytherapy fractions.
PocketNet matched nnU-Net accuracy for cervical MRI segmentation while using 40-fold less storage and approximately half the training time.
A 55-gene hypoxia classifier independently predicted worse survival and retained prognostic value across Manchester, Seoul, and Norwegian cervical cancer cohorts.
Iodine-125 seed implantation produced 90% three-month disease control, but median local progression-free survival was nine months.
Pretreatment lymphocyte-to-monocyte ratio was independently associated with cervical tumour shrinkage, but its standalone discrimination was poor.
EQD2 should remain the reporting standard, but delivery time, dose gradients, biological assumptions and dose accumulation materially affect its interpretation.
All patients receiving more than 8 Gy mean dose or 16 Gy maximum dose to the least exposed ovary developed premature ovarian insufficiency.
A score above seven identified patients with treatment beyond 56 days in 53.6% versus 17.8% at lower scores.
Adding radiotherapy to systemic treatment was associated with longer overall and progression-free survival without significantly higher acute toxicity.
A nodal-to-primary tumor volume ratio of at least 15% was associated with lower three-year distant metastasis-free survival after extended-field radiotherapy.
Induction chemotherapy showed no overall survival benefit, with outcomes differing by disease risk and the intensity of pre-radiotherapy treatment.
Semi-automated trajectory planning reduced workflow time and needle use while maintaining clinically acceptable target coverage and organ-at-risk doses.